The next Feinstein Visiting Professor Seminar Series lecture is scheduled for Monday, July 10, in the Goldman International Conference Center of the Feinstein Institute for Medical Research. Our guest speaker will be Cathy A. Swindlehurst, PhD, CEO of NovoMedix, LLC.
Dr. Swindlehurst will be presenting, “Novel Inhibitors Targeting the Mesenchymal Stem Cell Niche in Leukemia”, and will be hosted by Johnson Liu, MD.
Objectives: Upon completion of this session, participants should be able to:
Target Audience: Researchers, Students, Hospital-based physicians, Housestaff, Nurses, and Community physicians.
CME ACCREDITATION: Northwell Health is accredited by the Accreditation Council for Continuing Medical Education to provide Continuing Medical Education for physicians.
CREDIT DESIGNATION: Northwell Health designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
DISCLOSURE POLICY: Northwell Health adheres to the ACCME’s New Standards for Commercial Support. Any individuals in a position to control the content of a CME activity, including faculty, planners and managers, are required to disclose all financial relationships with commercial interests. All identified potential conflicts of interest are thoroughly vetted by Northwell Health for fair balance and scientific objectivity and to ensure appropriateness of patient care recommendations.
Planner and Speaker’s Disclosures: Nicholas Chiorazzi, MD, course director, and Bettie Steinberg, PhD, RSS planner, have no financial relationship to disclose. Guest speaker, Cathy A. Swindlehurst, PhD, has ownership interest in NovoMedix, LLC.
Recognition of Program Support: An announcement of program support will be made to all attendees at the beginning of each Regularly Scheduled Session.